ALTERED STRAIN OF THE MODIFIED VACCINA VIRUS ANKARA (MVA)
The invention provides new strains of the Modified Vaccinia Virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention als...
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
28.05.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides new strains of the Modified Vaccinia Virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention also provides a method for producing said adapted MVA strains. The adapted MVA can be used e.g. for parenteral immunization, as a vector system, or in the active or inactivated from as an adjuvant or as a regulator of the unspecific components of the immune system. |
---|---|
Bibliography: | Application Number: HUP0300120 |